Physician profile
Tyson J Corbin
NPI 1336407378
$4,588.01
in general payments reported to CMS, 2019-2025
21 companies · $858 in 2025
The $858 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $513 · 2022: $1,677 · 2023: $444 · 2024: $1,096 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.34 |
| Education | $168.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,812.55 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $665.38 | 2021-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $427.23 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.18 | 2021-2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $229.58 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $208.17 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $158.68 | 2022-2025 | Dupixent |
| Myriad Women'S Health, INC. | $132.22 | 2023 | Myrisk |
| Braintree Laboratories, INC. | $103.25 | 2021-2023 | Suflave, Sutab |
| Ardelyx, INC. | $88.31 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $83.03 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $79.81 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.35 | 2022 | |
| Celgene Corporation | $65.91 | 2022-2023 | Zeposia |
| Genzyme Corporation | $38.35 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $37.23 | 2024-2025 | Voquezna |
| Amgen INC. | $28.62 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.27 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $19.07 | 2025 | |
| Lilly USA, LLC | $18.75 | 2024 | Omvoh |
| Pfizer INC. | $16.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyson Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.